MAPT and Alzheimer disease: Somatic brain transgenesis could also be utilized to compare the resulting phenotype with different tau mutations, such as the V75A mutation for which pathogenicity remains undetermined (56), or the A152T variant which appears to modulate risk for AD and the spectrum of FTD disorders (57,58).